OPKO Health, Inc. Proceeds from Divestiture of Businesses
OPKO Health, Inc. (OPK) reported Proceeds from Divestiture of Businesses of $18.39 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2026-08-28
- OPKO Health, Inc. proceeds from divestiture of businesses for the quarter ending 2024-12-31 was $0.00.
- OPKO Health, Inc. proceeds from divestiture of businesses for the quarter ending 2023-12-31 was $0.00.
- OPKO Health, Inc. proceeds from divestiture of businesses for fiscal 2025 was $197.77M, a 5.99% decline from fiscal 2024.
- OPKO Health, Inc. proceeds from divestiture of businesses for fiscal 2024 was $210.38M.
- OPKO Health, Inc. proceeds from divestiture of businesses for fiscal 2023 was $0.00.
- OPKO Health, Inc. proceeds from divestiture of businesses for fiscal 2022 was $0.00.
| Period end | Proceeds from Divestiture of Businesses 1 month | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $18.39M 10-Q/A · filed 2026-08-28 | ||||
| 2025-12-31 | $197.77M 10-K · filed 2026-02-26 | ||||
| 2025-06-30 | $0.00 10-Q/A · filed 2026-08-28 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $210.38M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $210.38M 10-Q · filed 2024-11-07 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | ||||
| 2011-10-31 | $17.50M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |